Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-10-31

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cyclooxygenase-2 (COX-2) inhibitors have become a common analgesic treatment option for patients with arthritis. However, long-term treatment has been associated with increased cardiovascular risk. With the past withdrawals and rejections of approval for COX-2 inhibitors the treatment options are now very limited.

This translates for example to about 10 million osteoarthritis patients in the US who cannot receive COX-2 inhibitors because of concomitant hypertension. And this exemplifies the unmet medical need to develop and offer safe treatment options for this particular patient population.

This trial investigates pharmacodynamic aspects of CG100649 which is being developed as a novel COX-2 inhibitor. Preclinical data show a dual mechanism of action, which consists of the inhibition of the two enzymes COX-2 and carbonic anhydrase-I/-II (CA-I/II) and through which the cardiovascular risk of COX-2 inhibition might be attenuated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Variability in Response to Non-steroidal Anti-inflammatory Drugs

NCT02502006

Healthy

TERMINATED PHASE1

Anti-inflammatory Agents and Cholesterol Metabolism

NCT01279395

Osteoarthritis

TERMINATED

Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)

NCT00959439

Rheumatoid Arthritis Osteoarthritis

COMPLETED PHASE1

Phase I Study on Multiple Oral Dosing of CG100649

NCT01154790

Healthy

COMPLETED PHASE1

The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults

NCT04139824

Gout Hyperuricemia

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Part 1 and 2 (staged analysis): Single dose of study drugs \[celecoxib, placebo\] followed by 3 days of blood draws as Period I; then after a wash-out phase, single dose of study drugs \[CG100649 2mg and 8mg, celecoxib 200mg, placebo\], followed by blood draws on 6 days and bi-weekly urine collections for 8 weeks.

Part 3: Five-way cross-over of single doses of study drugs with a CG100649 single dose level as determined by part 1 and 2, celecoxib 200mg, naproxen 500mg, acetazolamide 250mg and placebo.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

CG100649, single oral dose of 2 mg

Group Type EXPERIMENTAL

CG100649 (2 mg)

Intervention Type DRUG

CG100649 capsules: 2 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).

2

CG100649, single oral dose of 8 mg

Group Type EXPERIMENTAL

CG100649 (8 mg)

Intervention Type DRUG

CG100649 capsules: 8 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).

3

Celecoxib, single oral dose of 200 mg

Group Type ACTIVE_COMPARATOR

Celecoxib

Intervention Type DRUG

Celecoxib (Celebrex®) capsules: 200 mg; single oral administration (Part 1 and 3)

4

Naproxen, single oral dose of 500 mg

Group Type ACTIVE_COMPARATOR

Naproxen

Intervention Type DRUG

Naproxen (Naprosyn®) tablets: 500 mg, single oral administration (Part 3)

5

Acetazolamide, single oral dose of 250 mg

Group Type ACTIVE_COMPARATOR

Acetazolamide

Intervention Type DRUG

Acetazolamide (generic, immediate release) tablets: 250 mg, single oral administration (Part 3)

6

Placebo, single oral administration

Group Type PLACEBO_COMPARATOR

Placebo capsules

Intervention Type DRUG

Placebo capsules: 198 mg silicified microcrystalline cellulose + 2 mg talc, multiple oral administrations (Part 1 and 3)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CG100649 (2 mg)

CG100649 capsules: 2 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).

Intervention Type DRUG

Celecoxib

Celecoxib (Celebrex®) capsules: 200 mg; single oral administration (Part 1 and 3)

Intervention Type DRUG

Placebo capsules

Placebo capsules: 198 mg silicified microcrystalline cellulose + 2 mg talc, multiple oral administrations (Part 1 and 3)

Intervention Type DRUG

Naproxen

Naproxen (Naprosyn®) tablets: 500 mg, single oral administration (Part 3)

Intervention Type DRUG

Acetazolamide

Acetazolamide (generic, immediate release) tablets: 250 mg, single oral administration (Part 3)

Intervention Type DRUG

CG100649 (8 mg)

CG100649 capsules: 8 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Celebrex® silicified microcrystalline cellulose Naprosyn®) generic Acetazolamide

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18-60 years old, able and willing to provide written informed consent to participate in the study;
2. Subjects must be in generally good health as determined by pre-study medical history, physical examination, clinical laboratory tests and 12-lead electrocardiogram (ECG);
3. Body mass index (BMI) 19-32 kg/m2;
4. Normal blood pressure (BP) \[systolic BP 90-140 mmHg, diastolic BP 50-90 mmHg\] and heart rate (HR) \[resting HR 45-90 bpm\] without medication;
5. Clinical chemistry profile including electrolytes, alkaline phosphatase (ALK), lactate dehydrogenase (LDH), creatine phosphokinase (CPK), creatinine, and urea must be within the normal range without medication; screening liver enzymes may be up to 1.5x normal range; screening CPK must be within 2x normal range without medication;
6. Urinalysis including urinary creatinine must be within normal limits (trace findings and minor deviations are acceptable per the clinical decision of the Principal Investigator);
7. Subjects must be non-smokers and non-drinkers or willing to abstain from smoking, alcohol, caffeine and high-fat foods for the duration of study;
8. Subjects must be able to read, understand and follow the study instructions;
9. Subjects and their sexual partners must agree to use double barrier contraception during the study period and for 2 months afterward or provide proof of surgical sterility. Double barrier contraception may include, but is not limited to, using a male condom with spermicide; having a female sexual partner who agrees to use an IUD with spermicide, a female condom with spermicide, a diaphragm with spermicide, a cervical cap with spermicide; or having a sterile sexual partner. Female subjects must be non-pregnant, non-lactating, and either postmenopausal for at least 1 year, surgically sterile for at least 3 months, or willing to use double barrier contraception from 28 days prior to study enrollment and/or their last confirmed menstrual period (whichever is longer) until 2 months after final clinic visit. For all females, the pregnancy test result must be negative at Screening;
10. Subjects must tolerate the insertion of an intravenous line of the size ≥ 20 gauge for the drug administration study days.

Exclusion Criteria

1. Use of any non-study medication(s) including low dose aspirin for cardiovascular prophylaxis within 2 weeks prior and 2 weeks after receipt of each dose of study drug;
2. Use of chemotherapy agents or history of cancer, other than non-metastatic skin cancer that has been completely excised, within five (5) years prior to the screening visit;
3. History of bacterial or viral infection requiring treatment with antibiotics or antivirals within 3 months of study;
4. Presence or history of peripheral edema within the past 5 years;
5. History of congestive heart failure;
6. Use of drugs which are P450 3A4 inducers or inhibitors within the past 30 days (e.g. alprazolam, chlorpheniramine, cimetidine, fluoxetine, haloperidol, ketoconazole, itraconazole, erythromycin, clarithromycin, sildenafil, simvastatin, St. John's Wort);
7. Use of prescribed systemic or topical medications or any dietary aids or foods that are known to modulate drug metabolizing enzymes (e.g. grapefruit juice) within 14 days of dose administration;
8. Difficulty in swallowing oral medications;
9. History of seizure disorder;
10. Serious psychosocial co-morbidities;
11. Cognitive or psychiatric disorders, or any other condition that could interfere with compliance with study procedures and/or confinement in a clinical study unit for 2 days or longer;
12. History of drug or alcohol abuse within one year prior to screening;
13. Use of any other investigational drug within 1 month prior to enrollment;
14. Use of any prescription drugs within 1 month prior to enrollment;
15. Use of over the counter medication excluding routine vitamins, but including mega-dose vitamin therapy, within one week of enrollment;
16. Donation and/or receipt of any blood or blood products within 3 months prior to enrollment;
17. Active gastrointestinal, renal, hepatic, or coagulant disorder within 1 month prior to enrollment;
18. Esophageal or gastroduodenal ulceration within 1 month prior to enrollment;
19. Hypersensitivity to NSAIDs, sulfonamides, COX-2 inhibitors, or carbonic anhydrase inhibitors;
20. Known allergy or hypersensitivity to sulfa drugs;
21. Family history of significant cardiac disease (i.e. sudden death in first degree relative; myocardial infarction prior to 50 years old);
22. Occult blood in stool (fecal occult blood test).

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes